Drug Trial Radar · NCT06925321
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
234
Planned (sponsor's estimate)
Start
Aug 26, 2025
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- Apr 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections. The study is looking for patients who have been diagnosed with invasive mold infections. The maximum study duration will be approximately 8 months, including a target study treatment duration of 84 days which can be extended up to 180 days and follow-up period. The patient will be assigned to one of two treatment cohorts: Cohort A (primary therapy): Patients will receive either the study drug or institutional standard of care antifungal treatment. Cohort B (salvage treatment; i.e. treatment given after patients did not respond to previous treatments or did not tolerate them): Patients will receive the study drug The primary aim is to compare the all cause mortality with a fixed threshold at Day 42.
Conditions
- Invasive Mold Infections
Interventions
Fosmanogepix IV infusionDrug
Fosmanogepix will be administered IV
Standard of care antifungal therapyDrug
Standard of care antifungal therapy will be administered in accordance with their respective product labels and/or standard practice guidelines
Fosmanogepix oral tabletDrug
Fosmanogepix will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Day 42 all-cause mortality rateTime frame: Day 42
Locations
90 sites in 15 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham School of Medicine, Department of Medicine
Birmingham, Alabama · Recruiting
City of Hope
Duarte, California · Recruiting
David Geffen School of Medicine at UCLA
Los Angeles, California · Recruiting
UC Davis Medical Center
Sacramento, California · Recruiting
Memorial Healthcare System
Hollywood, Florida · Recruiting
Rush University Medical Center, Division of Infectious Diseases
Chicago, Illinois · Recruiting
University of Kentucky Medical Center, Division of Infectious Diseases
Lexington, Kentucky · Recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
University of Michigan Health System (UMHS) - A. Alfred Taubman Health Care Center
Ann Arbor, Michigan · Recruiting
Karmanos Cancer Institute - Detroit
Detroit, Michigan · Terminated
University of Minnesota, M Health Fairview Medical Center
Minneapolis, Minnesota · Recruiting
Washington University School of Medicine, Infectious Diseases Clinical Research Unit
St Louis, Missouri · Recruiting
Weill Cornell Medical College - NewYork-Presbyterian Hospital
New York, New York · Recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Duke University Medical Center, Duke Infectious Diseases
Durham, North Carolina · Recruiting
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania · Recruiting
The University of Texas Health Science Center at Houston, Department of Internal Medicine
Houston, Texas · Recruiting
UT MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Texas Health Science Center at San Antonio
San Antonio, Texas · Recruiting
Monash Medical Center Clayton
Clayton, Australia · Recruiting
The Alfred Hospital
Melbourne, Australia · Recruiting
Peter MacCallum Cancer Center
Melbourne, Australia · Recruiting
Royal Melbourne Hospital
Parkville, Australia · Recruiting
Westmead Hospital
Westmead, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Australia · Recruiting
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia · Recruiting
Kepler University Hospital GmbH, Department of Internal Medicine IV - Pulmonology
Linz, Austria · Recruiting
Medical University Vienna, Department of Internal Medicine I, Clinical Department of Infections and Tropical Medicine
Vienna, Austria · Recruiting
General Hospital Saint-Jan
Bruges, Belgium · Recruiting
Charleroi Grand Hospital (GHDC) - Les Viviers Site
Charleroi, Belgium · Recruiting
Jessa Hospital
Hasselt, Belgium · Recruiting
University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology
Leuven, Belgium · Recruiting
UCL Mont-Godinne University Hospitals
Yvoir, Belgium · Recruiting
Porto Alegre Clinical Hospital (HCPA)
Porto Alegre, Brazil · Recruiting
Hospital A.C.Camargo ("Antonio Prudente" Foundation)
São Paulo, Brazil · Suspended
"Santa Marcelina" Hospital
São Paulo, Brazil · Recruiting
HC-UFPR
Curitiba, Paraná, Brazil · Recruiting
Hospital Our Lady of Grace
Curitiba, Paraná, Brazil · Recruiting
Paulista School of Medicine at Federal University of Sao Paulo, UNIFESP
São Paulo, São Paulo, Brazil · Recruiting
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.